The development of this advanced ultrasound system represents a pivotal shift in how breast cancer screenings are approached. Traditional mammography, which relies on X-rays, is effective but has notable limitations. Specifically, it often fails to identify aggressive tumors that may develop in the interim between routine screenings, commonly referred to as interval cancers. These types of tumors account for a staggering 20 to 30 percent of all breast cancer diagnoses and are generally considered more insidious. The rise of interval cancers underscores the urgent need for more regular and accessible ultrasound screenings.

The MIT team envisions a future where individuals can easily adopt ultrasound as a routine monitoring tool, thereby detecting tumors earlier and ultimately boosting survival rates. Current screening practices often limit ultrasound use to follow-up evaluations after a mammogram reveals a potential concern. The conventional ultrasound machines employed in these situations are large and costly, necessitating specialized training to operate. Addressing these barriers, the MIT innovators, led by Canan Dagdeviren, aim to democratize access to this life-saving technology, particularly for underserved populations or those living in remote regions.

In developing this new ultrasound system, the team reimagined the design to include an array of ultrasound transducers arranged in a compact, user-friendly probe. This innovative configuration facilitates real-time imaging by capturing a wide-angle 3D view of breast tissue. It represents a significant advancement over previous attempts, as the new system only requires scanning at two or three specific locations to generate comprehensive 3D images without the gaps that might be a concern with 2D systems.

The portability of this new device cannot be overstated. Unlike its traditional counterparts, which often necessitate bulky, expensive equipment that is confined to healthcare facilities, this new ultrasound probe can be paired with a laptop for immediate data processing. This capability allows for the visualization of detailed images on the go, making regular screenings much more feasible for individuals who might otherwise face obstacles in accessing traditional healthcare services.

One of the most exciting aspects of this technology is its potential for reducing the power requirements associated with traditional ultrasound devices. The new system is engineered to operate efficiently on a simple 5V DC supply, such as that used for small electronics. This feature not only enhances portability but also expands the potential user base, as it can be powered by readily available sources, including batteries commonly used for mobile devices.

The researchers validated their new system through trials conducted on human subjects, achieving promising results. For instance, they successfully demonstrated that their device could produce accurate 3D imaging of breast cysts in a patient with a history of breast-related health issues. The ability of the system to image up to 15 centimeters deep into breast tissue while maintaining the integrity of the images is a crucial milestone in the field of medical imaging.

Looking ahead, the MIT team is dedicated to further refining their technology. They envision creating an even smaller version of the data processing system, potentially the size of a fingernail, which could eventually interface with smartphones. Such advancements could lead to the development of mobile applications that guide users in utilizing the ultrasound device effectively, ensuring optimal positioning for accurate imaging results.

The overarching goal of this groundbreaking research is to mitigate inequalities in health care access. By facilitating at-home use of ultrasound technology for women at high risk of developing breast cancer, the team aims to encourage more frequent monitoring and earlier detection of abnormalities. As the technology progresses, Dagdeviren has expressed a commitment to translating these innovations into commercial solutions, with ongoing support from various MIT initiatives geared toward healthcare advancements.

This novel ultrasound system marks a decisive step forward in breast cancer detection and monitoring. By moving ultrasound technology beyond the boundaries of hospitals and into community settings, this research has the potential to save lives and transform the approach to breast health in ways previously unimagined. With continuing clinical trials and a view toward commercialization, the future of personalized ultrasound screening appears bright.

The implications of this technology extend beyond individual health benefits; they represent a significant advancement in the fight against breast cancer. By minimizing barriers to access and creating a versatile, affordable solution, the MIT team not only paves the way for improved outcomes but also sets a precedent for the future of healthcare innovation. The next few years will be crucial as they further develop this technology and its applications, potentially bringing life-saving screening to women around the world.

As research in this area progresses, the team’s commitment to expanding access to ultrasound technology shines a light on the intersection of engineering and healthcare. By harnessing advancements in miniaturization and data processing, they have crafted a solution that respects both patient needs and logistical realities—one that is poised to make a profound impact on breast cancer detection and ultimately save countless lives.

As this technology continues to evolve, it will be essential for practitioners, patients, and the medical community at large to stay informed. The research team is optimistic about the potential implications for healthcare practices worldwide, aiming to ultimately transform how breast cancer is monitored and diagnosed across diverse populations, thus building a more equitable healthcare landscape.

The road ahead is filled with opportunities and challenges as they navigate the regulatory landscape and clinical environments. The commitment to innovation at MIT, driven by the tenacity of the researchers involved, ensures that this technology will continue to improve, reaching new heights in its capabilities and accessibility.

Mitigating the impact of breast cancer on women’s health requires the advocacy of healthcare practitioners and the integration of innovative technologies like this ultrasound system. As they prepare for broader clinical trials and potential commercialization, the role of patient education will be paramount in maximizing the effective use of this device.

Through continued advancements, public awareness, and collaboration within the medical community, this new direction in ultrasound technology could redefine routine breast health practices, ensuring that early detection and effective monitoring become standard for all women at risk of breast cancer.

Subject of Research:
Article Title: Real-Time 3D Ultrasound Imaging with an Ultra-Sparse, Low Power Architecture
News Publication Date: 29-Jan-2026
Web References: DOI Link
References: Advanced Healthcare Materials
Image Credits: Conformable Decoders Lab at the MIT Media Lab

Keywords

• Health and Medicine
• Diseases and disorders
• Cancer
• Breast cancer
• Ultrasound
• Medical technology
• Medical equipment
• Engineering
• Human health
• Clinical medicine
• Medical treatments
• Biomedical engineering

Magnetostatic pumping leverages the principles of magnetism to facilitate fluid movement within a system, which in this case, is essential for ensuring adequate blood flow and oxygenation in patients experiencing severe respiratory failure or circulatory shock. Traditional ECMO devices, while effective, are often marred by various limitations, including mechanical complexities and logistical challenges regarding implantation and maintenance. The innovative approach described in this study offers a simplified, yet efficient alternative that could improve operational efficiency in high-stakes environments.

In their experiments, Zolala and his colleagues utilized an ex vivo model to simulate clinical conditions that would necessitate ECMO intervention. This model allowed them to manipulate variables and observe the effects of magnetostatic pumping in real-time, providing valuable insights into its potential efficacy and safety. By employing advanced imaging technologies, the team was able to track fluid dynamics and assess the function of the pump under various conditions, revealing noteworthy outcomes that could lead to enhanced patient survival rates.

One of the most striking findings of this study is the ability of the magnetostatic pump to maintain consistent blood flow rates while minimizing hemolysis – the destruction of red blood cells – a common complication associated with conventional ECMO systems. This breakthrough could significantly reduce the adverse effects often seen in patients requiring such complex interventions, a finding that is paramount in critical care medicine where patient stability is essential for recovery.

From a technical standpoint, the researchers meticulously detailed the design and operation of the magnetostatic pump. The mechanism involves the careful positioning of magnets that create a magnetic field strong enough to propel fluid through tubing, emulating the natural pulsatile flow of the heart. This innovative approach circumvents several mechanical components typically found in traditional pumps, reducing the overall footprint and complexity of the device, thus enhancing portability and ease of use in both hospital and field settings.

The research team also conducted extensive testing to compare the magnetostatic pump’s performance against conventional pneumatic pumps utilized in current ECMO technology. The results were promising; not only did they achieve superior flow rates, but the tactile feedback from the magnetostatic mechanism provided a greater sense of control during clinical applications. This creates exciting possibilities for medical professionals who often grapple with the unpredictability of current ECMO devices under stressful circumstances.

Furthermore, the study highlighted the ease of integration of the magnetostatic system with existing ECMO setups, allowing for a seamless transition for healthcare providers. Such adaptability is crucial in emergency medical situations, where time and efficiency can be the difference between life and death. This enhancement in procedural fluency is expected to be a vital contributor to positive clinical outcomes in critical care scenarios involving ECMO.

Another significant aspect of the research is its potential impact on healthcare costs. Given that ECMO procedures can be prohibitively expensive due to the complexity of the machines and the skilled personnel required to operate them, the introduction of a more straightforward and cost-effective method like magnetostatic pumping could lead to broader accessibility. If these systems can be manufactured at lower costs while maintaining or improving efficacy levels, healthcare facilities may be more inclined to adopt this technology, ultimately benefiting more patients in need of life-saving treatments.

The promising findings from the research also lay the groundwork for future studies aimed at optimizing magnetostatic pumping for various clinical applications beyond ECMO. For instance, applications in other scenarios requiring fluid transport, such as dialysis or infusion treatments, could be explored, expanding the utility of this innovative technology. This illustrates the versatility of magnetostatic principles, which may have far-reaching implications in medical engineering and patient care.

There remains, however, a need for further research to delineate the long-term effects and potential challenges associated with implementing magnetostatic pumps in clinical practice. The study by Zolala et al. is a critical starting point that highlights the need for additional controlled trials to validate their findings in diverse patient cohorts. The transition from experimental to widely adopted clinical practices is seldom straightforward, often necessitating rigorous testing and validation phases to ensure patient safety and device efficacy.

In conclusion, Zolala et al.’s research on magnetostatic pumping represents a significant advancement in ECMO technology with the potential to reshape patient care in critical medicine. As the medical community approaches the challenges of complex respiratory and circulatory support, innovations like this offer hope for improved outcomes and more efficient healthcare delivery. The possibility of healthier, more resilient patients in our hospitals could become a reality as we continue to innovate and refine life-saving technologies.

As the dust settles from this important research, one cannot help but feel a sense of anticipation for the next steps. The potential societal impact cannot be stressed enough, as advancements of this nature spark discussions not only in surgical rooms but also in boardrooms of healthcare facilities contemplating cost efficiencies. As we look forward to more breakthroughs, one can only imagine the lives that will benefit from these pioneering efforts in medical technology.

Subject of Research: Magnetostatic pumping in an ex vivo extracorporeal membrane oxygenation model.

Article Title: Magnetostaltic pumping in an ex vivo extracorporeal membrane oxygenation model.

Article References:

Zolala, M., Heim, V., Denis, C.V. et al. Magnetostaltic pumping in an ex vivo extracorporeal membrane oxygenation model.
J Transl Med (2026). https://doi.org/10.1186/s12967-026-07734-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-07734-w

Keywords: Magnetostatic pumping, extracorporeal membrane oxygenation, critical care technology, blood flow dynamics, hemolysis reduction, cost-effectiveness in healthcare.

Melanoma, one of the deadliest forms of skin cancer, often remains undetected until it reaches advanced stages where treatment becomes significantly more challenging. Early identification is foundational to improving patient prognosis and survival rates. As the prevalence of skin cancers rises globally, the necessity for efficient diagnostic solutions has never been more urgent. Traditional diagnostic methods heavily rely on the expertise of dermatologists, which can sometimes yield inconsistent results due to subjective interpretations. Thus, the integration of artificial intelligence into this field marks a transformative evolution.

The study leverages dermoscopy images, which are critical in the evaluation of skin lesions. These images provide intricate insights into skin features that are crucial for distinguishing between benign and malignant growths. However, manually analyzing dermoscopy images can be tedious and prone to error, underscoring the need for automated systems that can deliver accurate assessments.

By implementing a hybrid model that amalgamates the strengths of both CNNs and ANNs, the research team addressed the limitations often encountered in stand-alone systems. CNNs excel at extracting high-level features from images, leveraging deep learning architectures to recognize patterns that are not readily visible to the human eye. In contrast, ANNs contribute robust decision-making capabilities that utilize these features to enhance classification performance. The synergistic effect of combining these methodologies results in a powerful tool capable of discerning melanoma with improved precision.

This multifaceted approach begins at the preprocessing stage, where dermoscopy images are meticulously adjusted to ensure uniformity, thus optimizing the input for machine learning algorithms. Subsequent layers of CNN are designed to capture rich and complex features of skin lesions, progressively refining the image data to extract essential characteristics. The outputs from these convolutional layers are then funneled into the ANN, where sophisticated algorithms analyze the extracted features, culminating in a decisive classification of the images as benign or malignant.

In their experiments, the researchers utilized a comprehensive dataset comprising diverse dermoscopy images, ranging from common benign moles to various stages of melanoma. This diversity is crucial as it ensures that the model generalizes well across different skin types and conditions, a common challenge in dermatological diagnostics. The evaluation metrics used in the study reaffirmed the model’s effectiveness, showcasing notable improvements in accuracy, sensitivity, and specificity metrics over existing models.

Moreover, the study underscores the importance of explainability in AI-driven medical solutions. As healthcare professionals increasingly adopt AI tools, it becomes essential that these systems not only produce accurate results but also provide clear reasoning for their classifications. The architecture of the model designed in this study was enhanced to provide visual feedback on the decision-making process, allowing dermatologists to interpret AI findings more effectively and integrate them seamlessly into their clinical practices.

This research adds a significant layer of utility by presenting a robust framework that could potentially be integrated into current clinical systems, paving the way for real-time melanoma detection solutions in dermatology offices and hospitals across the globe. As AI technology evolves, its contributions to healthcare are destined to grow, transforming how medical professionals approach diagnostics and patient care.

The researchers have called for collaboration between technologists and healthcare practitioners to consistently refine these models further, making them even more tailored to specific populations. Cultural and geographical differences can influence the presentation of skin lesions, and thus the training datasets should reflect this diversity for broader applicability.

Additionally, the study opens doors for future explorations into integrating other forms of imaging technologies or data points, such as genetic markers, which could further enhance predictive capabilities. The potential for these AI-driven models to incorporate vast amounts of patient data creates a fertile ground for pioneering research that promises to redefine cancer care methodologies.

As this innovative modality permeates the medical landscape, it also brings important discussions about ethical considerations surrounding the deployment of AI in healthcare. Issues such as data privacy, algorithmic bias, and the need for regulatory frameworks are essential conversations as the technology matures. Ensuring that these systems function equitably and responsibly within society is paramount as we navigate the future of AI and medicine.

The team of Alshmrani, Alotaibi, and Alfakeeh is poised at the forefront of this transformative field, championing a model that not only enhances clinical accuracy but also bridges the gap between AI capabilities and practical applications in medicine. Their contributions underscore an exciting future in which technology and healthcare converge to enhance patient outcomes with unprecedented precision and reliability.

In conclusion, the fusion of multi CNN features with ANN represents an important advancement in the early classification of melanoma using dermoscopy images. By integrating cutting-edge machine learning techniques with rigorous medical analysis, this study not only showcases the potential of artificial intelligence but also highlights a pathway for improved diagnostic practices in dermatology, ultimately aiming to enhance patient care and outcomes in oncology.

Subject of Research: Early classification of melanoma using dermoscopy images through a hybrid model of CNN and ANN

Article Title: Fusion of multi CNN features with ANN for early classification of melanoma using dermoscopy images

Article References:

Alshmrani, A.S., Alotaibi, F.M. & Alfakeeh, A.S. Fusion of multi CNN features with ANN for early classification of melanoma using dermoscopy images.
Discov Sustain (2026). https://doi.org/10.1007/s43621-025-02556-0

Image Credits: AI Generated

DOI: 10.1007/s43621-025-02556-0

Keywords: melanoma, early classification, dermoscopy images, convolutional neural networks, artificial neural networks, machine learning, healthcare innovation, medical imaging, AI in dermatology, skin cancer detection.

Thyroid nodules are common findings, and while most are benign, a small percentage can be malignant. Consequently, the need for reliable diagnostic tools is pressing as these tools can significantly influence patient management strategies. Traditional diagnostic methods often rely heavily on invasive procedures, such as biopsies, which come with their own set of risks and complications, as well as the potential for increased healthcare costs and resource utilization. The innovative approach described in the study could pave the way for a shift from these invasive procedures to more accessible, less risky alternatives.

At the heart of this research is an interpretable multimodal machine learning model, designed not only to improve diagnostic precision but also to provide transparency in its decision-making process. One of the critical features of this model is its interpretability, which is essential in clinical settings where healthcare practitioners need to understand the rationale behind a machine’s predictions to build trust with patients. This aspect of the study highlights an essential progression in artificial intelligence: moving beyond the black-box models that lack transparency.

The model incorporates multiple data types to achieve more reliable predictions. This multimodal approach includes clinical information, imaging data, and pathological reports, enabling the algorithm to analyze and correlate various parameters affecting the diagnosis. By learning from diverse data sources, this machine learning model can mitigate the limitations often seen with unidimensional data, thus enhancing its predictive accuracy while also diminishing false negatives and false positives.

Moreover, the researchers tested their model on a comprehensive dataset, accumulating various cases across a spectrum of patient demographics and clinical presentations. By employing advanced algorithms, they were able to discern subtle patterns and correlations that a traditional approach might overlook. This data diversity not only reinforces the model’s validity but can serve as a crucial advantage in real-world applications where demographic variations prevail.

The implications of this research extend to low-resource environments where access to advanced diagnostic tools and specialist practitioners may be limited. In these contexts, the introduction of a reliable and accessible machine learning application can democratize patient care. Healthcare providers in these areas can leverage this technology to improve outcomes for patients who may otherwise not have access to timely and accurate cancer screenings.

One of the striking elements of the study was its emphasis on enabling healthcare providers in regions with fewer resources to utilize AI without requiring extensive technical training. The user-friendly design was a pivotal consideration during the development phase. In many low-resource settings, healthcare practitioners may have limited expertise in data science or computational methods, making intuitive systems essential for successful implementation.

The machine learning model’s adaptability allows it to refine its predictive capabilities over time. With continuous input of new data, it can learn and evolve, becoming increasingly accurate. The research team envisions a future where these systems can be updated regularly to incorporate the latest clinical findings and trends, ensuring sustained relevance and efficacy over time.

Significantly, the study reflects a growing recognition of the need for ethical considerations in deploying AI in healthcare settings. As technology advances, the study authors advocate for guidelines that prioritize patient safety and informed consent, particularly in AI applications where data privacy could become a concern. Addressing these ethical considerations up front is vital in maintaining public trust as healthcare increasingly turns to technological solutions.

Another important aspect of the research was its findings on the model’s performance in comparison to existing diagnostic benchmarks. In various metrics, the machine learning model exhibited superior predictive capabilities, demonstrating that technology could complement, if not surpass, traditional methods of evaluation. These comparative insights serve to validate the approach taken while opening the floor for further inquiry and exploration in the field.

In an era increasingly defined by rapid technological advancements, studies such as this reflect the remarkable intersections of healthcare, AI, and machine learning. The potential for innovation in this domain is immense, offering not just improvements in diagnostic capabilities but also a more human-centric approach to medicine, where ethical considerations play a crucial role.

The study serves as a clarion call, urging for further exploration into the capabilities of machine learning in various healthcare applications. As stakeholders and researchers alike share insights and experiences, the promise of enhanced healthcare delivery becomes a more achievable reality.

In summary, the findings delineated in the research conducted by Ma, F., Yu, F., and Gu, X. pose an exciting landscape for the future of thyroid nodule evaluations, particularly in regions necessitating innovative and feasible healthcare solutions. By harnessing the power of interpretable machine learning, the medical community is not just pushing the boundaries of technology; it is redefining them through compassionate and responsible applications.

With a commitment to addressing both clinical efficacy and ethical ramifications, the forthcoming developments in this domain foster a collective aspiration towards a more equitable healthcare future. As researchers continue to probe and innovate, the story of AI in medicine is poised to evolve, influencing generations of practices and patient outcomes to come.

Subject of Research: Machine learning model for predicting malignancy of thyroid nodules in low-resource scenarios.

Article Title: An interpretable multimodal machine learning model for predicting malignancy of thyroid nodules in low-resource scenarios.

Article References:

Ma, F., Yu, F., Gu, X. et al. An interpretable multimodal machine learning model for predicting malignancy of thyroid nodules in low-resource scenarios. BMC Endocr Disord 25, 232 (2025). https://doi.org/10.1186/s12902-025-02031-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12902-025-02031-x

Keywords: Thyroid nodules, machine learning, malignancy prediction, low-resource settings, interpretable AI, healthcare access, ethical AI, multimodal analysis.

Blood loss estimation is an essential aspect of patient care, especially in high-stakes environments like operating rooms or emergency departments. Traditional methods of measuring blood loss, including visual estimation and suction systems, often fall short regarding accuracy and reliability. These conventional techniques rely heavily on subjective interpretation, posing risks of underestimation or overestimation, which can lead to inappropriate clinical responses and potentially disastrous outcomes. The introduction of advanced analytical methods, such as the one presented by Chalermpan et al., could transform these outdated practices.

The researchers harnessed the power of computer vision technology to analyze color features associated with blood in various contexts and environments. Using sophisticated image processing algorithms, they developed a reliable method to differentiate between blood and other fluids or backgrounds. This step is fundamental, as the visual ambiguity in real-world scenarios can impede accurate blood loss assessment. By focusing on the unique attributes of blood color, clarity, and consistency, the researchers laid the groundwork for an efficient estimation process.

A critical component of their study was the application of gradient boosting trees, a machine learning technique known for its effectiveness in predictive modeling. This approach allows for the aggregation of weak learners to form a robust predictive model capable of handling complex patterns in data. By training their model on a diverse dataset that included different blood types, lighting conditions, and environmental variables, the researchers ensured that their blood loss estimation technique could be applicable in various real-world situations.

One of the most compelling aspects of this research is its potential to integrate seamlessly into existing clinical workflows. The method champions efficiency, promising to provide real-time assessments without requiring extensive additional resources or training for healthcare personnel. Utilizing cameras already present in operating rooms, the system could automatically assess blood loss, providing instant feedback to surgical teams, thereby enhancing decision-making processes during critical moments.

Moreover, the study underscores the importance of creating user-friendly interfaces that allow medical professionals to interpret the results easily. The interface could provide visual representations of blood loss estimates over time, offering clinicians the ability to react swiftly as circumstances evolve. Such visualizations could become invaluable not only during surgeries but also in managing trauma cases in emergency medicine, where every second counts.

As the researchers delve deeper into optimizing their model, the potential applications extend beyond immediate clinical use. In educational settings, the system could serve as a training tool for new medical personnel, equipping them with the skills to assess blood loss accurately and become adept at interpreting the data presented by the technology. This transference of knowledge can create a new generation of healthcare professionals who are well-versed in integrating technology into their medical practice.

The implications of this research also reach into the realm of telemedicine, where remote consultations are becoming increasingly popular. As virtual healthcare expands, clinicians often face challenges in assessing patient conditions without physical presence. Advanced blood loss estimation tools can be integrated into telehealth platforms, enabling healthcare providers to deliver more precise and timely assessments without being physically present at the site of care.

The collaborative efforts of the research team illustrate the interdisciplinary nature of modern medical innovations. By combining expertise in machine learning, computer vision, and clinical medicine, the study represents a synthesis of diverse fields working towards a common goal: improving patient outcomes. This collaborative approach could inspire future research initiatives where cross-disciplinary teams tackle pressing health challenges through innovative technologic solutions.

Additionally, the economic implications of implementing such technology are significant. Reduced variability in blood loss estimation can lead to improved resource allocations in hospitals, ultimately lowering operational costs while enhancing patient care delivery. Insurance companies may also recognize the benefits of precision medicine, potentially affecting reimbursement models related to surgical procedures.

The ongoing advancements in blood loss estimation systems are a testament to the rapid evolution in healthcare technology. However, transitioning from theoretical studies to mainstream clinical applications requires rigorous testing and validation across diverse healthcare settings. Future research could focus on longitudinal studies that assess the effectiveness of this technology over time, ensuring that it remains relevant and beneficial as healthcare needs evolve.

Finally, as this study sheds light on the pathways toward more reliable blood loss estimation, it leaves open crucial questions about the ethical implications of integrating machine learning into clinical practices. The reliance on technology must be balanced with vigilance to avoid potential over-dependence or the neglect of clinical judgment. Continuous education and training are necessary to ensure that healthcare providers remain competent and confident in their decision-making abilities.

In conclusion, the research led by T. Chalermpan and colleagues represents a significant leap forward in the estimation of blood loss during medical procedures. By leveraging advanced machine learning techniques and image analysis, the study showcases a transformative approach that addresses longstanding challenges in patient care. As these innovations move closer to practical application, they promise to reshape the landscape of clinical assessment, emphasizing the vital role of technology in enhancing medical outcomes.

Subject of Research: Blood loss estimation using color features and gradient boosting trees.

Article Title: Robust and efficient blood loss estimation using color features and gradient boosting trees.

Article References: Chalermpan, T., Gansawat, D., Kiratiratanapruk, K. et al. Robust and efficient blood loss estimation using color features and gradient boosting trees. Discov Artif Intell 5, 383 (2025). https://doi.org/10.1007/s44163-025-00619-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s44163-025-00619-9

Keywords: blood loss estimation, color features, gradient boosting trees, machine learning, medical technology, clinical assessment.

Staphylococcus aureus, a common bacterium often found on skin and nasal passages, poses a serious health risk due to its ability to develop resistance against multiple antibiotics. The rise of multidrug-resistant strains has confounded modern medicine, making infections increasingly difficult to treat and control. In this challenging context, researchers have been rigorously exploring alternative antimicrobial strategies that circumvent conventional antibiotic pathways, thus reducing the potential for resistance development.

The recent breakthrough involves the integration of wearable organic light-emitting diode (OLED) technology with natural antibacterial substances to create a synergistic antibacterial platform. OLED technology, well-known for its use in flexible screens and lighting, offers unique advantages when adapted for medical use: it is lightweight, flexible, and can be designed to emit precise wavelengths of light capable of disrupting bacterial pathogens. When combined with the inherent antimicrobial properties of certain natural compounds, this approach promises to deliver enhanced bactericidal effects against resistant strains.

Researchers focused on OLED devices that emit blue light, a spectrum well-documented for its ability to generate reactive oxygen species (ROS) in microbial cells. These ROS can cause oxidative damage to bacterial membranes and DNA, leading to bacterial cell death. The wearable format of OLEDs enables continuous, targeted exposure to this antibacterial light directly on the skin or wound sites, thus maximizing therapeutic efficacy without systemic side effects common in antibiotic treatments.

Complementing the photodynamic antimicrobial effect, the research incorporated natural antibacterial agents derived from plants known for their bioactive properties, such as essential oils, flavonoids, and phenolic compounds. These substances have been historically recognized for their ability to disrupt bacterial metabolism and biofilm formation, which is crucial because biofilms offer bacteria a protected environment against antibiotics. When combined with blue light exposure, these natural agents demonstrated a marked increase in their bactericidal activity.

Experimental validation involved exposing multidrug-resistant Staphylococcus aureus cultures to the combined treatment of wearable OLED light irradiation and topical application of natural antibacterial substances. The results showed a significantly enhanced inhibition of bacterial growth compared to either treatment used alone. This synergy suggests a promising route to effectively suppress or even eradicate stubborn bacterial populations that no longer respond to conventional antibiotics.

Another compelling advantage of this platform lies in its usability and convenience. Unlike systemic antibiotic therapies, which require strict dosing schedules and can cause adverse effects, the wearable OLED-based treatment can be easily applied and controlled by the user. This opens the door to personalized, ambulatory care models that empower patients to manage bacterial infections proactively in community or home settings.

From a technical perspective, the OLED devices are engineered to maintain stable emission intensities over extended periods, ensuring consistent antibacterial activity. The devices’ flexibility allows them to conform to various body contours such as joints or wound areas, overcoming one of the major limitations of traditional rigid light sources. Moreover, researchers have optimized the light intensity and wavelength to maximize ROS production without causing tissue damage, a crucial balance in phototherapy.

In addition to photodynamic and natural antimicrobial actions, the combined platform also appears to disrupt quorum sensing—a bacterial communication process that regulates virulence and resistance gene expression. By interfering with this signaling, the treatment not only attacks the bacteria directly but also diminishes their ability to coordinate defense mechanisms, increasing their susceptibility to clearance.

The implications of this research extend far beyond staphylococcal infections. The strategy could be adapted to target a variety of multidrug-resistant bacterial species that pose a threat in hospital and community environments. Given the flexibility of OLED fabrication and the diversity of natural antibacterial agents available, this platform is poised to become a versatile and scalable solution in the fight against antibiotic resistance.

Looking ahead, ongoing studies aim to further refine the wearable devices’ integration with biosensors, enabling real-time monitoring of infection biomarkers and dynamic adjustment of light therapy parameters. Such smart systems could revolutionize treatment personalization, reducing overtreatment risks and promoting optimal therapeutic outcomes.

As antibiotic resistance continues to endanger global health, innovative approaches like the OLED-natural substance synergy present a beacon of hope. By merging cutting-edge light-emitting technology with traditional antimicrobial wisdom, the research heralds a future where managing bacterial infections is safer, more effective, and accessible outside clinical settings.

This pioneering research underscores the critical importance of interdisciplinary collaboration, drawing from materials science, microbiology, photonics, and pharmacology. It embodies a paradigm shift toward non-invasive, resistance-mitigating therapies that align with modern healthcare’s demands for sustainability and patient-centeredness.

In conclusion, the combined use of wearable organic light-emitting diodes and natural antibacterial agents marks an exciting advancement in antimicrobial technology. Its ability to enhance antibacterial activity against multidrug-resistant Staphylococcus aureus and potentially other pathogens offers a promising new weapon in the global fight against drug-resistant infections. As further development continues, such innovations may soon become standard tools in individualized health management and infection control worldwide.

Subject of Research: Synergistic antibacterial activity of wearable organic light-emitting diodes combined with natural antibacterial substances against multidrug-resistant Staphylococcus aureus.

Article Title: Synergizing Wearable OLED Phototherapy and Natural Antibacterials to Combat Multidrug-Resistant Staphylococcus aureus.

News Publication Date:

Web References:

References:

Image Credits:

Keywords: wearable OLED, natural antibacterial substances, Staphylococcus aureus, multidrug resistance, photodynamic therapy, organic light-emitting diodes, antibacterial synergy, reactive oxygen species, biofilm disruption, antimicrobial resistance, health management, innovative infection control

Rare diseases, defined by the European Medicines Agency as those affecting fewer than five in 10,000 individuals, cumulatively impact approximately 300 million people globally, with around 36 million patients in the European Union alone. Despite their widespread collective prevalence, the traditional pharmaceutical development pipeline, with its reliance on centralized production of mass-market drugs, fails to adequately serve this diverse and fragmented patient population. The immense costs and complex logistics of producing individualized gene therapies have historically restricted access, leaving a significant treatment gap. NANOSPRESSO seeks to overturn these limitations by decentralizing the production of nucleic acid nanomedicines, tailoring therapies to patients’ unique genetic aberrations within hospital settings.

At the core of NANOSPRESSO lies the fusion of two validated biomedical technologies: nucleic acid therapeutics, which leverage RNA or DNA molecules to selectively target malfunctioning genes, and lipid nanoparticles (LNPs), engineered nanocarriers optimized for delivering these fragile molecules safely into cells. By encapsulating the nucleic acids within lipid carriers, the device ensures protection from enzymatic degradation and facilitates precise biodistribution, enabling the therapeutic cargo to reach the intended cellular targets effectively. The system’s microfluidic design mimics the precision and convenience of espresso machines, employing cartridge-based inputs that hospital pharmacists can load with lipid formulations and patient-specific genetic sequences to fabricate sterile, injectable nanomedicines on site.

This paradigm-shifting technology holds particular promise for the treatment of rare genetic diseases, many of which manifest early in life and often lack approved therapies due to the prohibitive costs associated with individualized drug development. Unlike conventional manufacturing, which caters to high-volume production and fails to economically justify small-batch therapeutics, NANOSPRESSO’s compact footprint and streamlined process could enable tailored medicines to be produced at the point of care. Such democratization of gene therapy manufacturing might significantly alleviate the disparities in healthcare access, bridging the gap between advanced medical technologies and under-resourced clinics across the globe.

The biological underpinnings of nucleic acid therapies are pivotal to their versatility. These therapeutics work by modulating gene expression through specifically designed RNA or DNA sequences that can silence, correct, or replace faulty genetic instructions responsible for disease phenotypes. Moreover, by altering the nucleic acid sequence payload, this treatment modality can rapidly pivot to address a myriad of conditions, ranging from monogenic inherited disorders, various malignancies, to infectious diseases where crucial viral or bacterial proteins need to be hindered. The high specificity of these therapies reduces off-target effects and enhances patient safety profiles.

NANOSPRESSO’s development has been spearheaded by a multidisciplinary team led by Professor Raymond Schiffelers at University Medical Center Utrecht. Their work builds on the successes of nucleic acid-based medicines, such as the mRNA vaccines deployed during the COVID-19 pandemic, demonstrating that clinically relevant, gene-targeted therapeutics can be produced efficiently and at scale. What sets NANOSPRESSO apart is its ability to condense the traditionally complex and resource-intensive manufacturing process into a user-friendly device operable by hospital pharmacists without requiring extensive specialized infrastructure.

Functionally, the device utilizes pre-loaded cartridges containing bespoke formulations of lipids and nucleic acids specific to the patient’s disease-causing mutation. These components are precisely combined within a sterile, closed-system microfluidic platform that facilitates controlled mixing and nanoparticle assembly in real time. The result is a homogenized suspension of nucleic acid-carrying lipid nanoparticles, formulated with rigor to meet stringent safety, efficacy, and sterility standards. The entire procedure circumvents the logistical and regulatory delays associated with centralized drug manufacturing and distribution, offering a just-in-time pharmaceutical manufacturing model.

Nevertheless, the introduction of such disruptive technology poses significant challenges to existing healthcare and regulatory frameworks. The notion of hospital-based production of gene therapies requires a re-evaluation of quality control systems, approval pathways, and liability construct to ensure patient safety without stifling innovation. The NANOSPRESSO team has proactively initiated dialogues with regulators and industry stakeholders to delineate pathways for compliance and integration, drawing parallels to the historical practice of pharmaceutical compounding, where pharmacists formulated personalized medicines prior to the industrialization of drug production.

Ethical and economic considerations also emerge as critical discourse points. By empowering local manufacturing, NANOSPRESSO could reduce drug costs substantially, making precision nanomedicine accessible beyond affluent nations and tertiary care centers. This localization may reduce healthcare disparities, particularly in rural or low-income regions traditionally marginalized in advanced therapy availability. However, implementing such technology demands robust training programs, standardized operating protocols, and integration within hospital pharmacy workflows to safeguard against variability and ensure reproducible therapeutic quality.

Currently, NANOSPRESSO prototypes are in active development, with ongoing research addressing technological refinement, pharmacological efficacy, biosafety, and integration logistics. Investigations are underway to validate the device’s performance across a spectrum of nucleic acid sequences and lipid formulations, simulate clinical deployment scenarios, and engage with healthcare providers to tailor operational models. The overarching ambition is to establish a scalable platform that seamlessly embeds into healthcare environments, enabling clinicians to harness personalized nanomedicines for diverse rare diseases and beyond.

By seamlessly bridging the gap between cutting-edge biotechnology and practical clinical application, NANOSPRESSO represents a beacon of innovation in the realm of personalized medicine. Its potential to transform the treatment landscape for millions suffering from rare genetic diseases is unparalleled, offering a vision of healthcare where medicines are no longer mass-produced commodities but precise, patient-customized interventions fabricated at bedside. As this technology matures and regulatory frameworks evolve, the promise of democratized gene therapy production draws nearer, heralding a new era of accessible precision health.

The project NANOSPRESSO-NL, supported by the Netherlands Science Agenda and the Netherlands Organization for Scientific Research, exemplifies how collaborative, interdisciplinary efforts can enable paradigm shifts in medical technology. The convergence of molecular biology, bioengineering, and clinical pharmacy embodied in NANOSPRESSO paves the way for a future where innovation transcends traditional manufacturing bottlenecks and empowers local healthcare providers to deliver next-generation therapies to patients irrespective of geography or resource constraints.

Subject of Research: Not applicable
Article Title: NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
News Publication Date: 26-Jun-2025
Web References: 10.3389/fsci.2025.1458636
Keywords: Personalized medicine, gene therapy, nucleic acid therapeutics, lipid nanoparticles, rare diseases, drug delivery systems, precision medicine, microfluidics, nanomedicine, healthcare equity, gene delivery, pharmacogenetics

The innovation pivots around a unique deep learning methodology termed the massive-training artificial neural network (MTANN). Unlike conventional AI systems, which demand vast datasets often requiring thousands or millions of annotated medical images, Suzuki’s MTANN thrives on remarkably minimal data. The system learns directly from pixel-level information extracted from computed tomography (CT) scans, drastically minimizing the training dataset to only 68 cases. This represents a colossal leap forward, circumventing the long-standing challenge of data scarcity in medical AI.

Cutting-edge deep learning architectures like Vision Transformer and 3D ResNet are usually the benchmarks in AI-based diagnosis, but Suzuki’s model outperforms these state-of-the-art (SOTA) frameworks despite their dependency on massive datasets. The MTANN approach achieved a remarkable area under the curve (AUC) of 0.92, compared to significantly lower scores from Vision Transformer and 3D ResNet models, which scored 0.53 and 0.59, respectively. This disparity underscores the efficacy of Suzuki’s approach, which also benefits from speed and portability.

Training efficiency is another standout feature of this MTANN model. Entirely trained on a commercial-grade laptop computer without specialized hardware, the process took a mere 8 minutes and 20 seconds — a fraction of the time and cost typically associated with large-scale AI training on data center infrastructures. Moreover, once trained, the system processes diagnostic predictions in just 47 milliseconds per patient case. This unprecedented speed not only streamlines clinical workflows but also expands AI’s accessibility to institutions with limited technological resources.

The implications of such technology go beyond mere cost and speed improvements. Suzuki emphasizes that this AI approach democratizes medical diagnostics, especially benefiting rare diseases where collecting extensive datasets is challenging or impossible. By reducing dependency on massive data volumes or expensive hardware, this innovation has the potential to empower healthcare providers worldwide — from well-equipped urban hospitals to rural clinics.

Another critical aspect of this breakthrough lies in its environmental impact. Conventional AI development and deployment, particularly those involving data centers filled with GPUs, pose enormous energy consumption challenges. The MTANN’s low resource demand translates into substantially reduced power usage, addressing the looming global energy concerns associated with the exponential growth in AI applications.

Suzuki’s research did not go unnoticed. At RSNA 2024, the work was honored with the prestigious Cum Laude Award, a distinction awarded to only 1.45% of all presentations. This recognition signifies the profound scientific value and impact potential embodied in the ultra-lightweight AI model — a testament to the team’s ingenuity and meticulous craftsmanship.

The MTANN concept has a storied history, dating back to Suzuki’s pioneering work in the early 2000s. Having developed one of the earliest deep learning models for medical imaging, Suzuki has continuously refined this technology over two and a half decades. With a prolific portfolio of over 400 scholarly articles and more than 40 patents — many of which have been commercialized — his work bridges the gap between cutting-edge AI theory and real-world clinical application.

His stature within the scientific community is exemplified not only by his research output but also through leadership roles, including chairing a session at the 39th Annual AAAI Conference on Artificial Intelligence. Furthermore, Suzuki received two of RSNA’s highest honors in 2024 and is ranked among the top 2% of scientists globally, cementing his influence in the AI and biomedical research arena.

Fostering interdisciplinary collaboration is a key driver behind Suzuki’s approach. Merging engineering, computer science, and medical knowledge, his team operates within a dynamic research environment that pushes the boundaries of biomedical AI. This synergy accelerates the translation of novel algorithms into practical diagnostic tools ready for real-world deployment, ensuring that theoretical breakthroughs positively impact patient care.

Looking forward, Suzuki and his collaborators envision expanding the scope of ultra-lightweight AI systems. Their work provides a blueprint for developing compact, high-performance models tailored to an array of medical imaging challenges, beyond lung cancer, and potentially other diagnostic modalities. This paradigm shift heralds a new era where AI’s power is harnessed efficiently, equitably, and sustainably.

The foundation of the Institute of Science Tokyo, officially established in October 2024 through the merger of Tokyo Medical and Dental University and Tokyo Institute of Technology, fosters this interdisciplinary and innovative atmosphere. With a mission centered on advancing science to enhance human wellbeing, the institute provides a fertile environment for breakthroughs such as Suzuki’s AI cancer diagnostic model.

In summation, the ultra-lightweight MTANN-based AI model stands as an extraordinary advancement in medical technology. It redefines the possibilities of AI diagnostics by combining efficiency, accessibility, and environmental responsibility. By enabling powerful diagnostic tools on everyday computing devices, its ripple effects could revolutionize cancer diagnosis globally, making high-quality healthcare attainable regardless of geographical or economic barriers.

Subject of Research: Artificial Intelligence for Lung Cancer Diagnosis

Article Title: Ultra-Lightweight AI Model Revolutionizes Lung Cancer Diagnosis on Standard Laptops

News Publication Date: 2024 (RSNA Annual Meeting)

Web References:

• Radiological Society of North America (RSNA) 2024 Annual Meeting: https://www.rsna.org/annual-meeting
• MTANN Deep Learning Approach: https://www.isct.ac.jp/ja/news/acnrfdt9dcto#note1
• AAAI Conference on Artificial Intelligence: https://aaai.org/conference/aaai/aaai-25/
• RSNA Highest Distinctions: https://suzukilab.first.iir.titech.ac.jp/news/news-4139/

Image Credits: Kenji Suzuki, Institute of Science Tokyo

Keywords: Cancer, Lung cancer, Artificial intelligence, Medical technology, Neural networks, Computerized axial tomography, Health and medicine, Cancer risk

The traditional stethoscope has been a staple in medical practice since its inception in 1816, serving as a primary tool for diagnosing various conditions through auscultation. However, despite its long-standing utility, the conventional device has its drawbacks, particularly when it comes to accuracy and precision. These limitations stem from a combination of factors such as the user’s expertise and the impact of ambient noise during examinations. While digital stethoscopes have made great strides in improving these areas, they fall short when it comes to convenience and usability. This is where the era of wearable technology initiates a profound transformation, offering more reliable and efficient solutions.

At the heart of this innovation lies the Lung–Sound–Monitoring–Patch (LSMP), a sophisticated component specifically engineered for capturing and analyzing respiratory sounds with remarkable precision. The LSMP comprises several key elements, including uni-directional and omni-directional MEMS microphones, a microcontroller unit, and a lithium polymer battery for adequate power supply. These components work in unison within an acoustic path that is meticulously designed to optimize sound signal acquisition. Furthermore, the entire device is encapsulated within a biocompatible resin enclosure, allowing for safe and comfortable attachment to the skin via medical-grade adhesive.

To validate the efficacy of the LSMP, comprehensive testing was conducted involving a range of subjects, from healthy individuals to patients with different respiratory conditions, including pediatric asthma and chronic obstructive pulmonary disease (COPD). During these tests, the LSMP demonstrated its ability to accurately differentiate between normal and abnormal breathing patterns, showcasing its potential in clinical settings. Notably, the device excelled in extracting vital metrics such as heart rate and respiratory rate from bioacoustic signals, establishing itself as a superior alternative to existing electronic stethoscopes.

In specific scenarios, such as analyses involving pediatric asthma patients, the LSMP effectively identified distinct wheezing signatures in real-time, facilitating a deeper understanding of abnormal breathing patterns. Conversely, when applied to elderly patients suffering from COPD, the LSMP faced challenges posed by noisy environments. Nevertheless, it managed to successfully classify normal and abnormal breathing sounds through advanced analytical techniques, including discrete and continuous wavelet transforms. These capabilities speak volumes about the LSMP’s robustness in diverse conditions, setting a new standard for respiratory monitoring.

An integral aspect of the LSMP’s functionality is its incorporation of an artificial intelligence-based algorithm, crafted from a two-dimensional convolutional neural network (CNN). This sophisticated algorithm allows for meticulous classification of breathing sounds and precise counting of wheezing events. To ensure high performance, the researchers trained this model utilizing a wealth of augmented lung-sound data, resulting in a remarkable match rate of approximately 80.5% during long-term clinical trials with COPD patients. This statistic underscores the algorithm’s accuracy and reliability in monitoring crucial respiratory indicators over extended periods.

Looking ahead, the researchers are optimistic about the potential applications of this wearable stethoscope in clinical practice. Future developments are expected to include the integration of active noise cancellation technology aimed at enhancing the device’s performance in daily activities. By facilitating consistent 24-hour monitoring, this wearable device has the potential to generate comprehensive datasets that can significantly inform medical decision-making processes. Such data can help clarify the intricate relationship between lung sounds, environmental changes, and treatment responses, paving the way for more personalized healthcare strategies.

Moreover, the impact of this groundbreaking wearable stethoscope may extend far beyond mere diagnostics; it could fundamentally alter how respiratory diseases are managed and treated. By providing healthcare professionals with a constant stream of data, they can proactively respond to changes in a patient’s condition, leading to timely interventions and improved patient outcomes. This level of real-time monitoring could revolutionize healthcare, particularly in the management of chronic conditions like asthma and COPD, where early detection of exacerbations is critical.

In a world increasingly reliant on technological innovations, the development of the LSMP exemplifies the exciting future of medical diagnostics. As the field of wearable technology continues to evolve, we can expect similar breakthroughs across various domains of health and medicine. Such advancements will not only enhance patient care but also contribute to a paradigm shift in how clinicians interact with and understand their patients’ conditions.

The research paper titled "A Wearable Stethoscope for Accurate Real-Time Lung Sound Monitoring and Automatic Wheezing Detection Based on an AI Algorithm" encapsulates these findings and elaborates on the various aspects of the study, establishing a comprehensive foundation for future investigations in this field. The collaborative efforts of the research team, including Kyoung-Ryul Lee, Taewi Kim, and several others, highlight the interdisciplinary nature of modern medical research and the importance of innovative thinking in overcoming the challenges posed by existing diagnostic tools.

As we stand on the precipice of a new era in medical technology, the potential of wearable devices in healthcare is just beginning to be realized. This wearable stethoscope represents not merely an advancement in diagnostic capabilities but symbolizes a broader shift towards more patient-centric care models that prioritize continuous monitoring and proactive healthcare strategies. The integration of technology into everyday healthcare practices promises to reshape our approach to medicine and ultimately lead to better health outcomes for individuals worldwide.

Subject of Research: Wearable stethoscope technology for lung sound monitoring
Article Title: A Wearable Stethoscope for Accurate Real-Time Lung Sound Monitoring and Automatic Wheezing Detection Based on an AI Algorithm
News Publication Date: 17-Jan-2025
Web References: DOI Link
References: Kyoung-Ryul Lee et al., Engineering, 2025
Image Credits: Kyoung-Ryul Lee et al.
Keywords: Wearable stethoscopes, lung sound monitoring, MEMS microphones, respiratory diagnostics, AI in healthcare

Access to potentially life-saving neurosurgical care remains very uneven worldwide, with potentially life-threatening consequences. This is especially true for a process called ventriculostomy, the most common neurosurgical procedure. Ventriculostomy involves the insertion of a catheter into the brain cavities called ventricles to drain cerebrospinal fluid and relieve intracranial pressure.

It’s a delicate, difficult process that requires extreme precision: misplacing the catheter, which happens in up to 30 per cent of freehand procedures, can result in hemorrhage, infection, prolonged hospital stays, morbidity and even death.

That’s why a group of Gina Cody School of Engineering and Computer Science researchers sought to improve access to low-cost technologies that can aid in improving ventriculostomy accuracy. Marta Kersten-Oertel, an associate professor in the Department of Computer Science and Software Engineering, and her team have developed an augmented-reality (AR)-based platform. They say it may make the procedure far safer and more accurate, especially in low- and middle-income countries and resource-limited settings.

The iSurgARy system uses LIDAR, a light detection and ranging technology, to help surgeons identify specific landmarks on the skull and accurately map them to the patient’s preoperative images (CT/MRI). Augmented reality is then used to project the ventricles onto the patient. The creators describe the technology in the Healthcare Technology Letters journal.

“The technology offers better spatial awareness of patient anatomy, which provides surgeons better aim at their target points,” says co-author Joshua Pardillo Castillo, MSc 24. “The augmented reality overlays the patient’s medical images to better see how they can best position the catheter.”

Precision brain mapping

LIDAR, available on Apple’s iOS devices, helps determine distances from the sensor to seven anatomical landmarks on the patient’s head: the tragus (the pointed eminence jutting out from the scalp at the front of the ear) on both sides of the head, the outer eyes, the inner eyes and the bridge of the nose. These landmarks are used to align the virtual models of the patient’s anatomy to the actual patient, providing the medical personnel with an augmented reality view that shows them where the ventricles are.

This visualization guides the clinician to the optimal location for catheter placement, while the catheter’s tracking tool can provide spatial understanding of the distance between the tip of the catheter and the ventricles.

“The AR view shows where the ventricles are so clinicians can decide on the best approach,” Kersten-Oertel explains. “The freehand technique relies on bony landmarks of the skull, and clinicians make their decision based on them. But if there is a brain tumour that is causing pressure or a traumatic brain injury, the brain may have shifted so the ventricles are not where they are expected to be. This system allows users to see the ventricles projected on the patient and accurately target them.”

The researchers point out that the platform emerged out of a practical need identified by an experienced clinician — David Sinclair, a clinical professor in cerebrovascular and skull base neurosurgery in the Division of Neurosurgery of McGill University’s Department of Neurology and Neurosurgery and a co-author on the paper. Sinclair asked Kersten-Oertel if it was possible to develop a tool that improves visualization to target ventricles in emergent scenarios where time, cost and accuracy are of utmost importance.

“This kind of collaboration with a neurosurgeon in the design and discovery phase makes this whole project unique,” says Zahra Asadi, a PhD student and co-first author on the paper.

“Working with him and getting to know the needs of the people who will be using this application is critical.”

Read the cited paper: “iSurgARy: A mobile augmented reality solution for ventriculostomy in resource-limited settings.”

Journal

Healthcare Technology Letters

DOI

10.1049/htl2.12118